DNA sequencing

Illumina Donates $1 Million in Sequencing Capabilities to Mumbai to Support Sequencing-Based COVID-19 Surveillance in India

Wednesday, August 4, 2021 - 2:30am

SAN DIEGO, Aug. 3, 2021 /PRNewswire/ --Illumina, Inc. (NASDAQ: ILMN) has donated $1 million in sequencing capabilities to the Molecular Diagnostic Reference Laboratory at Kasturba Hospital, in the Municipal Corporate of Greater Mumbai, to helpexpand SARS-CoV-2 sequencing capabilitiesin the region and support the broader genomic surveillance effort across India.

Key Points: 
  • SAN DIEGO, Aug. 3, 2021 /PRNewswire/ --Illumina, Inc. (NASDAQ: ILMN) has donated $1 million in sequencing capabilities to the Molecular Diagnostic Reference Laboratory at Kasturba Hospital, in the Municipal Corporate of Greater Mumbai, to helpexpand SARS-CoV-2 sequencing capabilitiesin the region and support the broader genomic surveillance effort across India.
  • Kasturba Hospital was the first hospital in Mumbai to begin sequencing SARS-CoV-2 this year and will examine how variants of the virus are being spread across India.
  • "Illumina believes in democratization of access to sequencing and we are committed to helping the regions of the world that carry most of the infectious disease burden to build genomics capabilities," said Francis deSouza, Chief Executive Officer of Illumina.
  • "This donation will help to make NGS technology and expertise accessible in Mumbai, supporting the region and contributing to genomic surveillance in India more broadly."

Pacific Biosciences Acquires Circulomics – A Leading High Molecular Weight DNA Extraction Company

Tuesday, August 3, 2021 - 1:00pm

MENLO PARK, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) (Pacific Biosciences or PacBio), a leading provider of high-quality, long-read sequencing platforms, announced today that it acquired Circulomics Inc. (Circulomics), a Maryland-based biotechnology company focused on delivering highly differentiated sample prep products that enable genomic workflows.

Key Points: 
  • MENLO PARK, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) (Pacific Biosciences or PacBio), a leading provider of high-quality, long-read sequencing platforms, announced today that it acquired Circulomics Inc. (Circulomics), a Maryland-based biotechnology company focused on delivering highly differentiated sample prep products that enable genomic workflows.
  • Scientists recognize Circulomics as a leader in extracting high quality, high molecular weight (HMW) DNA from almost any sample type.
  • High quality, long-read sequencing begins with high quality, long DNA.
  • Circulomics Nanobind magnetic disks protect DNA from shearing to generate long reads across a broad range of sample types.

Philips Genomics Workspace enables integration of the largest-scale FDA-cleared cancer genetic test at NYU Langone Health

Tuesday, August 3, 2021 - 2:00pm

This will enable the largest cancer sequencing test in the industry, helping to guide more confident treatment decisions and care pathways for patients who have received a cancer diagnosis.

Key Points: 
  • This will enable the largest cancer sequencing test in the industry, helping to guide more confident treatment decisions and care pathways for patients who have received a cancer diagnosis.
  • The number of genes cancer types assayed is the largest among academic genomic sequencing tests of its kind.
  • Philips Genomics Workspace, hosted on cloud-based Philips HealthSuite, will help facilitate the integration into the EMR so tests can be seamlessly ordered, reviewed, and shared by a patients care team.
  • With Philips Genomics Workspace, oncologists can map a patients uniquecharacteristics to a therapy that is best suited for them and provide evidence on why that therapy is preferable.

TwinStrand Biosciences Announces Filing of Patent Infringement Lawsuit Against Guardant Health

Tuesday, August 3, 2021 - 5:06pm

TwinStrand Biosciences, Inc. announced today that it filed a patent infringement lawsuit against Guardant Health, Inc. (Nasdaq: GH).

Key Points: 
  • TwinStrand Biosciences, Inc. announced today that it filed a patent infringement lawsuit against Guardant Health, Inc. (Nasdaq: GH).
  • TwinStrand and its exclusive licensor, the University of Washington, filed the lawsuit in the United States District Court in Delaware.
  • The complaint alleges that Guardant Health infringes multiple patents covering TwinStrands proprietary Duplex Sequencing methods for generating highly accurate DNA sequence data.
  • TwinStrand Biosciences is leading the way in identifying ultra-low frequency genomic variants that are undetectable by conventional methods.

Dermatology Industry Veteran Ann Deren-Lewis Joins Mindera as Chief Commercial Officer

Tuesday, August 3, 2021 - 1:00pm

"Ann has the demonstrated ability and distinct set of skills to support Mindera's efforts to shape the era of digital predictive skin analytics and lead the market in Dermal Intelligence," said George Mahaffey, CEO of Mindera.

Key Points: 
  • "Ann has the demonstrated ability and distinct set of skills to support Mindera's efforts to shape the era of digital predictive skin analytics and lead the market in Dermal Intelligence," said George Mahaffey, CEO of Mindera.
  • "Her experience in commercializing medical and aesthetic products and services, with an emphasis on psoriasis, is a perfect fit with our needs."
  • Mind.Px is the flagship test of Mindera Corporation.The Mindera platform uses a dermal biomarker patch that takes only minutes to extract vast transcriptomic information.
  • Subsequent Next-Generation Sequencing of the extracted RNA allows Mindera scientists to take a genetic and transcriptomic snapshot of the skin.

IASO Biotherapeutics’ World’s First Fully Human CD19/CD22 Dual-Targeted CAR-T Drug Receives Two IND Clearances, Enters Clinical Trials

Monday, August 2, 2021 - 1:00pm

Moreover, CT120 uses fully human antibody sequences, which can reduce the anti-drug antibody (ADA) effect and improve the in vivo persistence of CAR-T cells.

Key Points: 
  • Moreover, CT120 uses fully human antibody sequences, which can reduce the anti-drug antibody (ADA) effect and improve the in vivo persistence of CAR-T cells.
  • The CD19 antibody sequence of CT120 is developed on IASO Bios fully human antibody platform IMARS and high throughput CAR-T drug selection platform.
  • The companys high-throughput CAR-T drug selection platform, which uses cutting-edge single-cell analysis and next-generation sequencing (NGS) technology, can implement cost effective, high efficiency functional CAR-T candidate screening.
  • Adopting a fully human design, CT120 has low immunogenicity, reduces the ADA effect, and improves CAR-T cells viability.

Pillar Biosciences Appoints Dr. Eric Lai to its Board of Directors

Monday, August 2, 2021 - 1:00pm

Pillar Biosciences , an innovative next-generation sequencing (NGS) solutions in-vitro diagnostics (IVD) company, today announced the appointment of Eric Lai, Ph.D. to the Board of Directors.

Key Points: 
  • Pillar Biosciences , an innovative next-generation sequencing (NGS) solutions in-vitro diagnostics (IVD) company, today announced the appointment of Eric Lai, Ph.D. to the Board of Directors.
  • Dr. Lai brings more than 20 years of experience in drug and IVD molecular diagnostic development to the team at Pillar Biosciences.
  • I am excited to join the Board at Pillar Biosciences, to support the advancement of high-quality oncology diagnostic testing to enable precision medicine as the first option for every patient, said Dr. Eric Lai, Board Member, Pillar Biosciences.
  • Eric brings invaluable expertise to our team at Pillar, as we work to increase access to precision medicine, said Gang Song, Ph.D., Founder and CEO at Pillar Biosciences.

Delta Variant? There Are Others. Milford Molecular Diagnostics Laboratory Routinely Diagnoses Variants of SARS-CoV-2, Including Alpha, Beta, Gamma, Delta, Epsilon, Eta, Iota, Kappa and Lambda Variants

Thursday, July 29, 2021 - 7:17pm

Sin Hang Lee, director of Milford Molecular Diagnostics, summarizing recently published sequence-based surveillance data.

Key Points: 
  • Sin Hang Lee, director of Milford Molecular Diagnostics, summarizing recently published sequence-based surveillance data.
  • View the full release here: https://www.businesswire.com/news/home/20210729006029/en/
    However, he added, there exists no known diagnostic method for these variants in the U.S. for individual patient samples outside of Milford Diagnostics Laboratory.
  • All variants of concern or of interest must have at least one of these 8 mutated amino acids.
  • Milford Molecular Diagnostics Laboratory is CLIA-certified to perform nested RT-PCR/DNA sequencing for diagnosis of SARS-Co-V-2 and reflex spike protein gene sequencing for variant determination.

Illumina to Webcast Upcoming Investor Conference

Wednesday, July 28, 2021 - 11:30pm

Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference:

Key Points: 
  • Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference:
    UBS Genomics 2.0 and MedTech Innovations Summit on August 11, 2021
    The live webcast can be accessed under the Investor Info section of the "company" tab at www.illumina.com .
  • A replay will be posted on Illuminas website after the event and will be available for at least 30 days following.
  • Illumina is improving human health by unlocking the power of the genome.
  • Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments.

Pacific Biosciences Grants Equity Incentive Award to New Employee

Wednesday, July 28, 2021 - 9:05pm

MENLO PARK, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (Pacific Biosciences or the Company), a leading provider of high-quality sequencing platforms, today announced that the Compensation Committee of the Companys Board of Directors granted restricted stock units (RSUs) covering 29,500 shares of Pacific Biosciences common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the 2020 Inducement Plan) effective on July 22, 2021 (the Effective Date).

Key Points: 
  • MENLO PARK, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (Pacific Biosciences or the Company), a leading provider of high-quality sequencing platforms, today announced that the Compensation Committee of the Companys Board of Directors granted restricted stock units (RSUs) covering 29,500 shares of Pacific Biosciences common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the 2020 Inducement Plan) effective on July 22, 2021 (the Effective Date).
  • The award of RSUs is subject to the terms and conditions of the 2020 Inducement Plan and the applicable award agreement entered into with the employee.
  • Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing.
  • Cited in thousands of peer-reviewed publications, PacBio sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology.